摘要
目的探究原发性开角型青光眼患者采用曲伏前列素滴眼液治疗的临床效果与安全性。方法选取的92例(184眼)原发性开角型青光眼患者都来自该院门诊2016年4月-2018年4月期间诊治的患者,并按照双盲法分为两组,实验组予以曲伏前列素滴眼液治疗,对比组予以马来酸噻吗洛尔滴眼液治疗,并对比两组治疗效果、不同时间眼压水平、视力、散光度与不良反应发生率。结果对比组治疗总有效率81.52%,低于实验组的93.48%(χ^2=6.012 4,P=0.0142);实验组治疗2周、4周、8周后的眼压水平分别为(16.30±0.43)mmHg、(16.09±0.55)mmHg、(16.01±0.55)mmHg,低于治疗前的(27.52±2.29)mmHg(P<0.05),对比组治疗2周、4周、8周后的眼压水平分别为(17.51±0.47)mmHg、(16.82±0.50)mmHg、(16.77±0.59)mmHg,低于治疗前的(27.66±2.38)mmHg(P<0.05),且实验组治疗2周、4周、8周后的眼压水平低于对比组(t=18.218 9、9.420 0、9.037 5,P<0.05);治疗后实验组视力与散光度水平分别为(0.81±0.22),(1.05±0.84)D,优于治疗前的(0.05±0.03),(4.40±1.47)D(P<0.05);治疗后对比组视力与散光度水平分别为(0.45±0.13),(2.56±1.00)D,优于治疗前的(0.06±0.04),(4.51±1.65)D(P<0.05);且实验组治疗后视力与散光度水平优于对比组(t=13.512 6、11.090 0,P<0.05);对比组不良反应发生率51.08%,高于实验组的22.83%(χ^2=15.768 8,P=0.000 0)。结论原发性开角型青光眼患者采用曲伏前列素滴眼液的治疗效果效果,安全性较高。
Objective To investigate the clinical efficacy and safety of travoprost eye drops in patients with primary open angle glaucoma.Methods 92 patients (184 eyes) with primary open-angle glaucoma were conveniently selected in our hospital from April 2016 to April 2018.They were divided into two groups according to the double-blind method.The experimental group received travoprost.Eye drops in the observation group,timolol maleate eye drops in the comparison group,and the therapeutic effects,intraocular pressure levels,visual acuity,astigmatism and adverse reaction rates were compared between the two groups.Results The total effective rate of the treatment group was 81.52%,which was lower than that of the experimental group 93.48%(χ^2=6.012 4,P=0.014 2).The intraocular pressure levels of the experimental group after treatment for 2 weeks,4 weeks and 8 weeks were (16.30±0.43) mmHg,(16.09±0.55) mmHg,(16.01±0.55) mmHg,lower than (27.52±2.29) mmHg before treatment (P<0.05),the intraocular pressure levels in the control group after 2 weeks,4 weeks,and 8 weeks were (17.51±0.47)mmHg,(16.82±0.50) mmHg,(16.77±0.59) mmHg,lower than before treatment (27.66±2.38)mmHg(P<0.05),and the intraocular pressure level in the experimental group after 2 weeks,4 weeks,and 8 weeks was lower than that in the control group (t=18.218 9、9.420 0、9.037 5,P<0.05);after treatment,the visual acuity and astigmatism levels of the experimental group were (0.81±0.22) and (1.05±0.84)D,respectively.It was better than (0.05±0.03) and (4.40±1.47)D before treatment(P<0.05);the visual acuity and astigmatism level of the contrast group after treatment were respectively (0.45±0.13),(2.56±1.00)D,better than (0.06±0.04),(4.51±1.65)D before treatment(P<0.05);The visual acuity and astigmatism level after treatment were better than that of the control group(t=13.512 6、11.090 0,P<0.05);the incidence of adverse reactions in the control group was 51.08%,which was higher than that in the experimental group22.83%(χ^2=15.768 8,P=0.000 0).Conclusion The effect of the treatment effect of travoprost eye drops in patients with primary open angle glaucoma is higher and the safety is higher.
作者
林金香
戴追
LIN Jin-xiang;DAI Zhui(Department of Ophthalmology,Qidong People's Hospital,Qidong,Jiangsu Province,226200 China)
出处
《中外医疗》
2019年第23期82-85,共4页
China & Foreign Medical Treatment
